Liver resection surgery versus thermal ablation for colorectal liver metastases
ISRCTN | ISRCTN52040363 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN52040363 |
Secondary identifying numbers | 20592 |
- Submission date
- 09/03/2016
- Registration date
- 09/03/2016
- Last edited
- 11/05/2020
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Contact information
Ms Julie Croft
Public
Public
University of Leeds
Clinical Trials Research Unit
17 Springfield Mount
Leeds
LS2 9JT
United Kingdom
Study information
Study design | Randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
Scientific title | LAVA: Liver resection surgery versus thermal Ablation for colorectal liVer metAstases |
Study acronym | LAVA |
Study objectives | The aim of this study is to compare the effectiveness of liver resection surgery and thermal ablation for the treatment of colorectal liver metastases. |
Ethics approval(s) | 16/LO/0058 |
Health condition(s) or problem(s) studied | Topic: Surgery; Subtopic: Surgery; Disease: Surgery (All Surgery) |
Intervention | Participants are randomly allocated to one of two treatment groups. Surgical resection: Surgical liver resection will be performed in accordance with each site’s usual practice. Patients may be offered open or laparoscopic liver resection depending on site and stage of disease. Procedures for patients with extensive metastatic disease can include two stage liver resection, venous embolization, or the ALPPS procedure (Associated Liver Partition and Portal vein ligation for Staged hepatectomy). Thermal ablation: Either radiofrequency ablation (RFA) or microwave ablation (MWA) will be carried out according to the local availability of equipment and expertise. Ablation may be performed at laparoscopic or open surgery if the percutaneous approach is contra-indicated. |
Intervention type | Procedure/Surgery |
Primary outcome measure | Disease free survival at 2 years is calculated from participant assessments at 3, 6, 12, 18 and 24 months post-randomisation |
Secondary outcome measures | 1. Local and distant recurrence of disease at 2 years is calculated from participant assessments at 3, 6, 12, 18 and 24 months post-randomisation 2. Overall survival is determined at 2 and 5 years post-randomisation 3. Post treatment complications are recorded at participant assessments at 3, 6, 12, 18 and 24 months post-randomisation 4. Disease free survival (DFS) (measured from end of intervention) at 2 years post-randomisation 5. Use of subsequent therapies for treatment failure over 2 years post-randomisation 6. Health related quality of life is measured using EQ-5D, EORTC QLQ-C30, EORTC LMC21 at baseline 3 and 6 months post randomisation 7. Length of intensive therapy unit (ITU) and inpatient stay 8. Resource use collected retrospectively at 3, 6, 12, 18, and 24 months post-randomisation |
Overall study start date | 01/10/2016 |
Completion date | 30/09/2020 |
Reason abandoned (if study stopped) | Participant recruitment issue |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | Planned Sample Size: 330; UK Sample Size: 252 |
Total final enrolment | 9 |
Key inclusion criteria | 1. Aged ≥ 18 years 2. Able to provide written informed consent 3. MDT diagnosis of colorectal liver metastases considered to be resectable with curative intent 4. Resected colorectal primary or plan for primary resection with curative intent 5. Meets one or more of the following criteria: 5.1. Considered high risk for surgery due to age e.g. Age greater than 75 years of age 5.2. Major co-morbidities as judged by the treating clinician. Examples include history of myocardial infarction, severe chronic airway disease, major cerebrovascular accidents (CVA), pulmonary embolism (PE) 5.3. Liver metastases with poor prognosis and or high risk surgery due to tumour burden, Examples include extensive synchronous disease, need for two stage resection or ALLPS, small anticipated remnant liver volume, resectable or ablatable extra-hepatic disease, downstaged with chemotherapy, poor response after chemotherapy or portal vein embolization but still resectable 6. Suitable candidate for either liver resection surgery or thermal ablation as judged by the MDT 7. Able and willing to comply with the terms of the protocol including QoL questionnaire |
Key exclusion criteria | 1. Incurable extra-hepatic metastases 2. Concurrent malignant disease (except basal cell carcinoma) 3. Patients who have undergone previous surgery or ablation for colorectal liver metastases 4. Planned simultaneous resection for primary and liver metastases disease 5. Pregnancy |
Date of first enrolment | 01/10/2016 |
Date of final enrolment | 30/09/2020 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
University of Leeds
Clinical Trials Research Unit
17 Springfield Mount
Leeds
LS2 9JT
United Kingdom
17 Springfield Mount
Leeds
LS2 9JT
United Kingdom
Sponsor information
University College London
Hospital/treatment centre
Hospital/treatment centre
R&D (1st Floor, Maple House)
Rossenheim Building
235 Euston Road
London
NW1 2BU
England
United Kingdom
https://ror.org/02jx3x895 |
Funders
Funder type
Government
National Institute for Health Research
Government organisation / National government
Government organisation / National government
- Alternative name(s)
- National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
- Location
- United Kingdom
Results and Publications
Intention to publish date | 31/08/2019 |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Protocol article | protocol | 13/02/2018 | Yes | No | |
Results article | results | 01/04/2020 | 11/05/2020 | Yes | No |
HRA research summary | 28/06/2023 | No | No |
Editorial Notes
11/05/2020: Publication reference and total final enrolment number added.
23/11/2018: The trial was stopped on 31/08/2018 due to recruitment issues. The intention to publish date was changed from 30/09/2021 to 31/08/2019.
15/02/2018: Publication reference added.
20/03/2017: Cancer Help UK lay summary link added to plain English summary field.